Skip to contentpdufa.bio
Home › Decisions › GSK 2026-11-17

Nelkarmi (neladalkib) FDA accelerated approval for ALK-positive NSCLC: Nov 17, 2026

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET
✓ APPROVED

Nelkarmi (Neladalkib (NVL-655)) was approved by the FDA on November 17, 2026 for adults with locally advanced or metastatic ALK-positive NSCLC previously treated with one prior ALK TKI consisting of alectinib, or with two or more prior ALK TKIs and platinum-based chemotherapy (accelerated approval).

Verified against: FDA action day November 17, 2026 (FDA accelerated approval notification) · Announcement November 17, 2026 (GSK plc press release) · Goal date November 27, 2026 (Nuvalent press release).

This page was first committed to pdufa.bio's public repository on Nov 17, 2026, 4:20 PM ET (public commit b552701). Dates on this page are the FDA's and the sponsor's; this line is ours.

The FDA granted accelerated approval to Nelkarmi (neladalkib) on November 17, 2026 for adults with previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer, on the single-arm ALKOVE-1 study, 10 days before its November 27 goal date.

Run-up into the decision (T-120 → T+0)

FDA decision 11/17/26$53.71$46.275/28/26FDA decision 11/17/26$53.71$46.275/28/26
Daily close, T-120 (5/28/26) through T+0. Run-up high $53.71 on 7/28/26, low $46.27 on 10/13/26 (T-120 to T-1). FDA decision 11/17/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-11-17
OutcomeApproved
Drug / candidateNelkarmi (neladalkib)
IndicationPreviously treated locally advanced or metastatic ALK-positive NSCLC: after alectinib as the only ALK TKI, or after two or more ALK TKIs and platinum chemotherapy (accelerated approval)
CompanyGSK plc
Market-cap tierLarge
120-day run-up (T-120→T-1)-2.3%
Decision-day move-2.3%
Move measured on2026-11-17 close, against the 2026-11-16 close
Cohort decision-day move (history)1.0% median (n=828)

The FDA's notification states that on November 17, 2026 it granted accelerated approval to neladalkib (Nelkarmi, Nuvalent, Inc.) for adults with locally advanced or metastatic ALK-positive NSCLC who previously received one prior ALK TKI consisting of alectinib, or two or more prior ALK TKIs and platinum-based chemotherapy (FDA, November 17, 2026). GSK, which acquired Nuvalent in July 2026, announced the approval the same day from London (GSK's announcement). The PDUFA goal date was November 27, 2026, assigned when the NDA was accepted with Priority Review (Nuvalent, May 27, 2026); the FDA acted 10 days early. The FDA's letter had not been posted on Drugs@FDA when this page was published. Per the FDA, in ALKOVE-1 (NCT05384626) confirmed overall response by blinded independent central review was 49% (95% CI 37 to 62) in 67 patients after alectinib and 32% (95% CI 24 to 40) in 155 patients after two or more ALK TKIs and platinum-based chemotherapy; 52% and 51% of responders had a response lasting at least 12 months. Neladalkib holds Breakthrough Therapy and Orphan Drug designations; continued approval may be contingent on a confirmatory trial.

Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier. History, not a prediction.

Primary source: FDA accelerated approval notification, November 17, 2026

FDA record of the action: the FDA approved on November 17, 2026, per FDA accelerated approval notification, November 17, 2026 (letter not yet on Drugs@FDA) (FDA notice). The sponsor announced it the same day. Action dates on pdufa.bio come from the FDA's own record, not the press release. Every FDA action we hold, by FDA date: FDA approval letters.

Questions

Was neladalkib approved by the FDA?

Yes. The FDA granted accelerated approval on November 17, 2026 to neladalkib (Nelkarmi) for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer previously treated with alectinib as the only ALK inhibitor, or with two or more ALK inhibitors and platinum-based chemotherapy, per the FDA's own notification. GSK announced it the same day. Continued approval may depend on a confirmatory trial.

Which company is behind Nelkarmi (neladalkib)?

Nelkarmi (neladalkib) is a GSK plc (GSK) program. The FDA decision came on November 17, 2026; the company's own announcement is linked on this page.

How did GSK stock react to the FDA decision?

GSK moved -2.3%, measured as the 2026-11-17 close against the 2026-11-16 close. It is one trading day's move, so it can include news other than the decision. Historical measurement, not a prediction, and not investment advice.

Was the neladalkib decision early?

Yes, by 10 days. The FDA acted on November 17, 2026; the goal date was November 27, 2026, as stated by Nuvalent when the application was accepted with Priority Review (May 27, 2026). GSK's release also says the approval came ahead of the original target action date.

What did ALKOVE-1 show?

Per the FDA, confirmed overall response by blinded independent central review was 49% in 67 patients whose only prior ALK inhibitor was alectinib and 32% in 155 patients after two or more ALK inhibitors and platinum-based chemotherapy. Among responders, 52% and 51% respectively had responses lasting at least 12 months.